Literature DB >> 25169971

Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5.

Kristin V T Engebretsen1, Kristine Skårdal2, Sigrid Bjørnstad3, Henriette S Marstein1, Biljana Skrbic1, Ivar Sjaastad2, Geir Christensen2, Johannes L Bjørnstad1, Theis Tønnessen4.   

Abstract

Pressure overload-induced TGF-β signaling activates cardiac fibroblasts (CFB) and leads to increased extracellular matrix (ECM) protein synthesis including fibrosis. Excessive ECM accumulation may in turn affect cardiac function contributing to development of heart failure. The aim of this study was to examine the effects of SM16, an orally active small molecular inhibitor of ALK5, on pressure overload-induced cardiac fibrosis. One week after aortic banding (AB), C57Bl/6J mice were randomized to standard chow or chow with SM16. Sham operated animals served as controls. Following 4 weeks AB, mice were characterized by echocardiography and cardiovascular magnetic resonance before sacrifice. SM16 abolished phosphorylation of SMAD2 induced by AB in vivo and by TGF-β in CFB in vitro. Interestingly, Masson Trichrome and Picrosirius Red stained myocardial left ventricular tissue revealed reduced development of fibrosis and collagen cross-linking following AB in the SM16 treated group, which was confirmed by reduced hydroxyproline incorporation. Furthermore, treatment with SM16 attenuated mRNA expression following induction of AB in vivo and stimulation with TGF-β in CFB in vitro of Col1a2, the cross-linking enzyme LOX, and the pro-fibrotic glycoproteins SPARC and osteopontin. Reduced ECM synthesis by CFB and a reduction in myocardial stiffness due to attenuated development of fibrosis and collagen cross-linking might have contributed to the improved diastolic function and cardiac output seen in vivo, in combination with reduced lung weight and ANP expression by treatment with SM16. Despite these beneficial effects on cardiac function and development of heart failure, mice treated with SM16 exhibited increased mortality, increased LV dilatation and inflammatory heart valve lesions that may limit the use of SM16 and possibly also other small molecular inhibitors of ALK5, as future therapeutic drugs.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac fibroblasts; Cardiac fibrosis; Glycoproteins; Heart failure; Pressure overload

Mesh:

Substances:

Year:  2014        PMID: 25169971     DOI: 10.1016/j.yjmcc.2014.08.008

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  31 in total

Review 1.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

2.  A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure.

Authors:  Jessica M Bradley; Pablo Spaletra; Zhen Li; Thomas E Sharp; Traci T Goodchild; Laura G Corral; Leah Fung; Kyle W H Chan; Robert W Sullivan; Cathy A Swindlehurst; David J Lefer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-27       Impact factor: 4.733

Review 3.  Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD.

Authors:  Noam Jacob; Stephan R Targan; David Q Shih
Journal:  United European Gastroenterol J       Date:  2016-05-10       Impact factor: 4.623

Review 4.  Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure.

Authors:  J Heger; R Schulz; G Euler
Journal:  Br J Pharmacol       Date:  2015-11-16       Impact factor: 8.739

Review 5.  Cardiac Fibrosis: The Fibroblast Awakens.

Authors:  Joshua G Travers; Fadia A Kamal; Jeffrey Robbins; Katherine E Yutzey; Burns C Blaxall
Journal:  Circ Res       Date:  2016-03-18       Impact factor: 17.367

6.  The Increased Transforming Growth Factor-β Signaling Induced by Diabetes Protects Retinal Vessels.

Authors:  Zeina Dagher; Chiara Gerhardinger; Joseph Vaz; Michael Goodridge; Francesco Tecilazich; Mara Lorenzi
Journal:  Am J Pathol       Date:  2017-02-02       Impact factor: 4.307

Review 7.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

8.  Targeting the transforming growth factor (TGF)-β cascade in the remodeling heart: benefits and perils.

Authors:  Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2014-09-11       Impact factor: 5.000

Review 9.  Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges.

Authors:  Amit Saxena; Ilaria Russo; Nikolaos G Frangogiannis
Journal:  Transl Res       Date:  2015-07-17       Impact factor: 7.012

Review 10.  The role of Smad signaling cascades in cardiac fibrosis.

Authors:  Anis Hanna; Claudio Humeres; Nikolaos G Frangogiannis
Journal:  Cell Signal       Date:  2020-11-05       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.